Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
Clinical trial NCT05206812 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05206812
- Sponsor
- Yonsei University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2027-01-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.